Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which completed Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montréal, Canada.

Period	dileps
2019-12-31	N/A
2020-12-31	-$1.70
2021-12-31	-$1.02
2022-12-31	-$1.38
2023-12-31	-$1.39
2024-12-31	-$0.67

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MIST	$2.00	-0.50%	3.37M
3
4
5

Milestone Pharmaceuticals Inc. (MIST) Earnings Per Share (EPS)

EPS (Earnings Per Share) Data

Get Milestone Pharmaceuticals Inc. Data in Excel

More MIST Financial Data